OSE Immunotherapeutics (XPAR:OSE) YoY EBITDA Growth : 43.51% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is OSE Immunotherapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. OSE Immunotherapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 43.51%.

OSE Immunotherapeutics's EBITDA per Share for the six months ended in Dec. 2023 was €-0.41.

OSE Immunotherapeutics YoY EBITDA Growth Historical Data

The historical data trend for OSE Immunotherapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OSE Immunotherapeutics YoY EBITDA Growth Chart

OSE Immunotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

-115.79

-2,072.22

35.55

6.35

-26.41

OSE Immunotherapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial															77.33	102.85	-344.17	-2,982.35	43.51

OSE Immunotherapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

OSE Immunotherapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-0.895	-	-0.708)	/	\| -0.708 \|
=	-26.41 %

OSE Immunotherapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.409	-	-0.724)	/	\| -0.724 \|
=	43.51 %

OSE Immunotherapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of OSE Immunotherapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

OSE Immunotherapeutics (XPAR:OSE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OSE Immunotherapeutics SA (XPAR:OSE) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

6OP:Germany

Address

22, Boulevard Benoni Goullin, Nantes, FRA, 44200

Website

http://www.ose-immuno.com

OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.

OSE Immunotherapeutics (XPAR:OSE) Headlines

No Headlines